Ascendis Pharma is a publicly traded company trading on NASDAQ, led by CEO Jan Moller Mikkelsen.
Upcoming earnings announcement for Ascendis Pharma
Past 12 earnings reports for Ascendis Pharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | Q4 2025 | -$0.64Est: -$0.06 | -966.7% | $288.1MEst: $289.7M | -0.5% | — |
| Nov 12, 2025 | Q3 2025 | -$1.17Est: -$0.41 | -185.1% | $249.8MEst: $248.6M | +0.5% | — |
| Aug 7, 2025 | Q2 2025 | -$0.93Est: -$1.42 | +34.5% | $179.2MEst: $162.8M | +10.1% | — |
| May 1, 2025 | Q1 2025 | -$1.66Est: -$1.51 | -9.9% | $106.2MEst: $94.9M | +11.9% | — |
| Feb 12, 2025 | Q4 2024 | -$0.68Est: -$1.20 | +43.3% | $185.6MEst: $122.5M | +51.5% | — |
| Nov 14, 2024 | Q3 2024 | -$1.89Est: -$1.52 | -24.3% | $63.6MEst: $70.3M | -9.6% | — |
| Sep 3, 2024 | Q2 2024 | -$2.06Est: -$1.56 | -32.1% | $38.8MEst: $92.7M | -58.2% | — |
| May 2, 2024 | Q1 2024 | -$2.50 | — | $104.1M | — | — |
| Feb 7, 2024 | Q4 2023 | -$1.66Est: -$2.15 | +22.8% | $148.2MEst: $97.0M | +52.8% | — |
| Nov 7, 2023 | Q3 2023 | -$3.13Est: -$2.75 | -13.8% | $52.3MEst: $52.7M | -0.8% | — |
| Sep 5, 2023 | Q2 2023 | -$2.35Est: -$2.68 | +12.3% | $51.7MEst: $41.7M | +23.8% | — |
| Apr 27, 2023 | Q1 2023 | -$2.13 | — | $36.0M | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.